Article

Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity.

Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA.
Pediatric Blood & Cancer (Impact Factor: 2.56). 12/2004; 43(7):723-8. DOI: 10.1002/pbc.20077
Source: PubMed

ABSTRACT Better predictors of outcome would allow improved risk-adapted therapy for pediatric nonmetastatic osteosarcoma of the extremity. We investigated the predictive value of MR imaging-based measures of absolute and relative tumor size and volume at the time of diagnosis. We also assessed the relation of tumor size to age and histologic response.
We retrospectively abstracted demographic, treatment history, and outcome information of patients treated on a single institutional protocol. A single pediatric oncologic radiologist manually measured each primary lesion and the affected native bone in three dimensions on MR images obtained at the time of diagnosis. Eight parameters of tumor size were analyzed for their value in predicting overall survival (OS) and event-free survival (EFS).
The median age of the 42 patients was 13.5 years (range: 5.9-18.7 years); 50% were female and 74% were Caucasian. Absolute tumor volume was an important predictor of OS (P < 0.05); absolute tumor depth (analyzed as a continuous variable) was a significant predictor of OS (P = 0.018) and EFS (P = 0.036). Relative measures of tumor size were not found to predict outcome. No relation was seen between tumor size and histologic response.
Absolute tumor size at the time of diagnosis is significantly predictive of OS and EFS. If validated in a larger study, this indicator should be used in the design of risk-adapted treatment protocols for osteosarcoma.

0 Bookmarks
 · 
151 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: In dogs with appendicular osteosarcoma (OSA), increased pretreatment serum bone-specific alkaline phosphatase (BALP) activity is a negative prognostic factor, associated with shorter disease-free intervals and survival times, but a biologic basis for observed differential serum BALP activities in canine OSA patients remains incompletely defined. OBJECTIVE: Serum BALP activity will correlate with absolute tumor burden in dogs with OSA. ANIMALS: This study included 96 client-owned dogs with appendicular OSA. METHODS: In canine OSA cell lines, the expression and membranous release of BALP was evaluated in vitro. The correlation between serum BALP activity and radiographic primary tumor size was evaluated in OSA-bearing dogs. In dogs developing visceral OSA metastases, serial changes in serum BALP activities were evaluated in relation to progression of macroscopic metastases, and visceral metastatic OSA cells were evaluated for BALP expression. RESULTS: In vitro, BALP expression was not associated with either tumorigenic or metastatic phenotype, rather the quantity of membranous BALP released was proportional with cell density. In dogs devoid of macroscopic metastases, there was a positive correlation between serum BALP activity and absolute primary tumor size. In dogs with progressive OSA metastases, serum BALP activity increased and coincided with the development of macroscopic metastases. OSA cells derived from visceral metastatic lesions retained BALP expression. CONCLUSIONS AND CLINICAL IMPORTANCE: Tumor burden is a determinant of serum BALP activity in dogs with appendicular OSA. The association between increased pretreatment BALP activity and negative clinical prognosis may simply be attributed to greater initial tumor burden, and consequently more advanced tumor stage.
    Journal of Veterinary Internal Medicine 06/2013; · 2.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In children malignancies have characteristics distinct from tumors occurring in adults. For instance, the reported incidence is substantially lower, varying from 90 to 170 cases per 1,000,000 child years. Long-term event-free survival rates above 80% are noted in several tumors. Biology is essentially different; in pediatrics the number of mutations is limited and they are linked with specific malignancies, whereas in adults an accumulation of multiple mutations is assumed. Hereditary factors are noted in several neoplasm's. Although the linkage of syndromes with specific tumors is known for a prolonged time, currently the link with minor congenital anomalies in specific tumor types gets more prominent. Environmental factors related with an increased or a decreased risk of cancer are noted.In this review an update is given on tumor biology and treatment for several tumors, i.e. neuroblastoma, Ewing sarcoma, osteosarcoma, nephroblastoma, rhabdomyosarcoma, hepatoblastoma and retinoblastoma. Among the aspects dealt with are the occurrence of spontaneous remissions, I-meta-iodobenzylguanidine (MIBG) imaging and treatment, apoptosis induction, antisense therapy, immunotherapy, tyrosin kinase inhibition, stem cell transplantation, suicide gene therapy and anti-angiogenic therapy.
    Update on Cancer Therapeutics 09/2006; 1(3):367-383.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The receptor activator of NF-κB (RANK) signalling pathway represents a promising target for the therapy of bone-related tumours. In the present study we evaluated the impact of the expression of RANK and its ligand (RANKL) on survival and response to chemotherapy in osteosarcoma patients.Expression of RANK and RANKL was examined in 91 human osteosarcomas by immunohistochemistry using formalin fixed, paraffin embedded (FFPE) tumour samples. Results of the stainings were correlated with clinicopathological parameters and patient survival.Sixty-three osteosarcomas (69.2%) expressed RANK, whereas only eight cases (8.8%) showed expression of RANKL. Expression of RANK was significantly associated with shorter disease-free survival by Kaplan-Meier analysis (p = 0.031). We further observed worse response to chemotherapy in RANK expressing tumours, which was statistically not significant (p = 0.099). RANKL expression was significantly more frequent in osteosarcoma of the lower extremity than in any other location. Analysis of RANKL expression did not reveal any statistically significant correlation with disease-free or osteosarcoma-specific survival.In our study, we identified RANK expression as a negative prognostic factor regarding disease-free survival in osteosarcoma. Moreover, RANK might modulate response of human osteosarcoma to chemotherapy. Therefore, RANK signalling cascade is likely to provide a novel alternative to targeted therapy of osteosarcoma and deserves further investigation.
    Pathology 05/2014; · 2.62 Impact Factor